Cellenkos Inc. Enters Regulatory T-Cell Platform Research Collaboration with MD Anderson

November 15th 2017

Houston, TX, November 15, 2017 -- Cellenkos Inc. has announced a multi-year collaboration with The University of Texas MD Anderson Cancer Center focused on development of cord blood regulatory T cell (CB TREG) therapeutics for treatment of autoimmune disease and inflammatory disorders. As part of this collaboration, Cellenkos Inc. will fund up to 10,000,000 USD over the next 5 years to establish and support the TREG Program at MD Anderson. This program will be led by Dr. Simrit Parmar, Chief, Section of Autoimmune Diseases and Inflammatory Disorders and Dr. Varsha Gandhi, Chair, Department of Experimental Therapeutics.

Golden Meditech and MD Anderson Team Up to Create Cellenkos, Inc.

September 18th 2016

HONG KONG and HOUSTON, Sept. 18, 2016 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company"), a Hong Kong-based integrated healthcare enterprise, and The University of Texas at MD Anderson Cancer Center ("MD Anderson") have announced the creation of Cellenkos, Inc. ("Cellenkos"), a start-up enterprise focused on umbilical cord blood derived T-regulatory ("T-reg") cellular therapies.

2 Next →